questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines et peptides de signalisation intracellulaire
Protein-Serine-Threonine Kinases
Aurora kinases
Aurora kinases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Kinases Aurora
Diagnostic médical
Marqueurs tumoraux
Kinases Aurora
Cancer du sein
Kinases Aurora
Phosphorylation
Kinases Aurora
Analyse sanguine
Kinases Aurora
Symptômes
5
Symptômes du cancer
Kinases Aurora
Division cellulaire
Kinases Aurora
Signes précoces de cancer
Kinases Aurora
Symptômes neurologiques
Kinases Aurora
Croissance tumorale
Kinases Aurora
Prévention
5
Prévention du cancer
Kinases Aurora
Dépistage du cancer
Kinases Aurora
Mode de vie sain
Kinases Aurora
Antioxydants
Kinases Aurora
Vaccination
Kinases Aurora
Traitements
5
Inhibiteurs de kinases
Kinases Aurora
Efficacité des traitements
Kinases Aurora
Effets secondaires
Kinases Aurora
Chimiothérapie
Kinases Aurora
Essais cliniques
Kinases Aurora
Complications
5
Complications du cancer
Kinases Aurora
Métastases
Kinases Aurora
Pronostic du cancer
Kinases Aurora
Complications des traitements
Kinases Aurora
Réponse immunitaire
Kinases Aurora
Facteurs de risque
5
Facteurs de risque
Kinases Aurora
Alimentation
Kinases Aurora
Infections virales
Kinases Aurora
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Aurora kinases : Questions médicales les plus fréquentes",
"headline": "Aurora kinases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Aurora kinases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-30",
"dateModified": "2025-03-25",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Aurora kinases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protein-Serine-Threonine Kinases",
"url": "https://questionsmedicales.fr/mesh/D017346",
"about": {
"@type": "MedicalCondition",
"name": "Protein-Serine-Threonine Kinases",
"code": {
"@type": "MedicalCode",
"code": "D017346",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Aurora kinase A",
"alternateName": "Aurora Kinase A",
"url": "https://questionsmedicales.fr/mesh/D064096",
"about": {
"@type": "MedicalCondition",
"name": "Aurora kinase A",
"code": {
"@type": "MedicalCode",
"code": "D064096",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.103.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Aurora kinase B",
"alternateName": "Aurora Kinase B",
"url": "https://questionsmedicales.fr/mesh/D064107",
"about": {
"@type": "MedicalCondition",
"name": "Aurora kinase B",
"code": {
"@type": "MedicalCode",
"code": "D064107",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.103.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Aurora kinase C",
"alternateName": "Aurora Kinase C",
"url": "https://questionsmedicales.fr/mesh/D064108",
"about": {
"@type": "MedicalCondition",
"name": "Aurora kinase C",
"code": {
"@type": "MedicalCode",
"code": "D064108",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.103.875"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Aurora kinases",
"alternateName": "Aurora Kinases",
"code": {
"@type": "MedicalCode",
"code": "D064127",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Karen Schindler",
"url": "https://questionsmedicales.fr/author/Karen%20Schindler",
"affiliation": {
"@type": "Organization",
"name": "Department of Genetics, Rutgers University, Piscataway, NJ 08854, USA."
}
},
{
"@type": "Person",
"name": "Cecilia S Blengini",
"url": "https://questionsmedicales.fr/author/Cecilia%20S%20Blengini",
"affiliation": {
"@type": "Organization",
"name": "Department of Genetics; Rutgers, The State University of New Jersey, Piscataway, New Jersey, United States of America."
}
},
{
"@type": "Person",
"name": "Mansour Aboelenain",
"url": "https://questionsmedicales.fr/author/Mansour%20Aboelenain",
"affiliation": {
"@type": "Organization",
"name": "Department of Genetics, Rutgers University, Piscataway, NJ 08854, USA."
}
},
{
"@type": "Person",
"name": "Jing Wang",
"url": "https://questionsmedicales.fr/author/Jing%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Oncology, the First Affiliated Hospital of Gannan Medical College, Ganzhou, China."
}
},
{
"@type": "Person",
"name": "Tao Guo",
"url": "https://questionsmedicales.fr/author/Tao%20Guo",
"affiliation": {
"@type": "Organization",
"name": "Department of Thoracic surgery, the First Affiliated Hospital of Dalian Medical University, Dalian, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system.",
"datePublished": "2023-04-03",
"url": "https://questionsmedicales.fr/article/37019248",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.neubiorev.2023.105155"
}
},
{
"@type": "ScholarlyArticle",
"name": "Real-World Outcomes of Proprotein Convertase Subtilisin Kexin-9 Inhibitor Use.",
"datePublished": "2023-05-01",
"url": "https://questionsmedicales.fr/article/36795508",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/FJC.0000000000001404"
}
},
{
"@type": "ScholarlyArticle",
"name": "Assessment of serum proprotein convertase subtilisin/kexin type 9 in pediatric sepsis syndrome.",
"datePublished": "2024-07-07",
"url": "https://questionsmedicales.fr/article/38972879",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-65609-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis.",
"datePublished": "2022-07-27",
"url": "https://questionsmedicales.fr/article/35508401",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/heartjnl-2021-320556"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association between proprotein convertase subtilisin/kexin type 9 and subclinical cerebrovascular disease in the community.",
"datePublished": "2023-02-16",
"url": "https://questionsmedicales.fr/article/36727585",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ene.15723"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protein-Serine-Threonine Kinases",
"item": "https://questionsmedicales.fr/mesh/D017346"
},
{
"@type": "ListItem",
"position": 6,
"name": "Aurora kinases",
"item": "https://questionsmedicales.fr/mesh/D064127"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Aurora kinases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Aurora kinases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Aurora kinases",
"description": "Comment diagnostiquer une anomalie des kinases Aurora ?\nQuels marqueurs sont associés aux kinases Aurora ?\nLes kinases Aurora sont-elles liées à des cancers spécifiques ?\nQuels tests sont utilisés pour évaluer l'activité des kinases Aurora ?\nPeut-on détecter les kinases Aurora dans le sang ?",
"url": "https://questionsmedicales.fr/mesh/D064127?mesh_terms=Proprotein+Convertase+9#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Aurora kinases",
"description": "Quels symptômes sont liés à une dysrégulation des kinases Aurora ?\nLes kinases Aurora affectent-elles la division cellulaire ?\nY a-t-il des signes précoces de cancer liés aux kinases Aurora ?\nLes kinases Aurora sont-elles impliquées dans des symptômes neurologiques ?\nComment les kinases Aurora influencent-elles la croissance tumorale ?",
"url": "https://questionsmedicales.fr/mesh/D064127?mesh_terms=Proprotein+Convertase+9#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Aurora kinases",
"description": "Peut-on prévenir les anomalies des kinases Aurora ?\nLes dépistages réguliers aident-ils à détecter les problèmes liés aux kinases Aurora ?\nY a-t-il des facteurs de mode de vie influençant les kinases Aurora ?\nLes antioxydants aident-ils à prévenir les anomalies des kinases Aurora ?\nLes vaccinations peuvent-elles prévenir les cancers liés aux kinases Aurora ?",
"url": "https://questionsmedicales.fr/mesh/D064127?mesh_terms=Proprotein+Convertase+9#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Aurora kinases",
"description": "Quels traitements ciblent les kinases Aurora ?\nLes inhibiteurs de kinases Aurora sont-ils efficaces ?\nQuels effets secondaires peuvent résulter des traitements ciblant les kinases Aurora ?\nLes traitements ciblant les kinases Aurora sont-ils combinés avec d'autres thérapies ?\nY a-t-il des essais cliniques sur les kinases Aurora ?",
"url": "https://questionsmedicales.fr/mesh/D064127?mesh_terms=Proprotein+Convertase+9#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Aurora kinases",
"description": "Quelles complications peuvent survenir avec des anomalies des kinases Aurora ?\nLes anomalies des kinases Aurora augmentent-elles le risque de métastases ?\nComment les anomalies des kinases Aurora affectent-elles le pronostic ?\nLes complications des traitements ciblant les kinases Aurora sont-elles fréquentes ?\nLes anomalies des kinases Aurora peuvent-elles affecter la réponse immunitaire ?",
"url": "https://questionsmedicales.fr/mesh/D064127?mesh_terms=Proprotein+Convertase+9#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Aurora kinases",
"description": "Quels sont les facteurs de risque associés aux anomalies des kinases Aurora ?\nL'âge influence-t-il le risque d'anomalies des kinases Aurora ?\nLe tabagisme est-il un facteur de risque pour les kinases Aurora ?\nL'alimentation joue-t-elle un rôle dans les anomalies des kinases Aurora ?\nLes infections virales sont-elles liées aux anomalies des kinases Aurora ?",
"url": "https://questionsmedicales.fr/mesh/D064127?mesh_terms=Proprotein+Convertase+9#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie des kinases Aurora ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de tissus tumoraux peuvent révéler des anomalies."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés aux kinases Aurora ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux d'expression des kinases Aurora A et B peuvent servir de marqueurs tumoraux."
}
},
{
"@type": "Question",
"name": "Les kinases Aurora sont-elles liées à des cancers spécifiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont souvent surexprimées dans des cancers comme le sein et le poumon."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des kinases Aurora ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de phosphorylation et des analyses de Western blot sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Peut-on détecter les kinases Aurora dans le sang ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, la détection se fait principalement dans les tissus tumoraux, pas dans le sang."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une dysrégulation des kinases Aurora ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient selon le cancer, mais peuvent inclure fatigue, douleur et perte de poids."
}
},
{
"@type": "Question",
"name": "Les kinases Aurora affectent-elles la division cellulaire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles jouent un rôle clé dans la mitose, et leur dysfonction peut entraîner des anomalies cellulaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes précoces de cancer liés aux kinases Aurora ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes précoces peuvent inclure des changements inexpliqués dans le corps, mais sont souvent vagues."
}
},
{
"@type": "Question",
"name": "Les kinases Aurora sont-elles impliquées dans des symptômes neurologiques ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent un lien entre les kinases Aurora et des troubles neurologiques dans certains cancers."
}
},
{
"@type": "Question",
"name": "Comment les kinases Aurora influencent-elles la croissance tumorale ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles régulent la mitose, et leur surexpression peut conduire à une croissance tumorale incontrôlée."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies des kinases Aurora ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode spécifique, mais un mode de vie sain peut réduire le risque de cancer."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers aident-ils à détecter les problèmes liés aux kinases Aurora ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dépistages réguliers peuvent aider à détecter des cancers associés aux anomalies des kinases."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs de mode de vie influençant les kinases Aurora ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et l'exercice peuvent influencer la santé cellulaire et réduire les risques."
}
},
{
"@type": "Question",
"name": "Les antioxydants aident-ils à prévenir les anomalies des kinases Aurora ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent que les antioxydants peuvent réduire le stress oxydatif, mais des recherches sont nécessaires."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles prévenir les cancers liés aux kinases Aurora ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations, comme celles contre le HPV, peuvent réduire le risque de cancers spécifiques."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les kinases Aurora ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques des kinases Aurora sont en développement pour traiter divers cancers."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs de kinases Aurora sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent qu'ils peuvent réduire la croissance tumorale, mais des recherches sont nécessaires."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent résulter des traitements ciblant les kinases Aurora ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure nausées, fatigue et troubles hématologiques."
}
},
{
"@type": "Question",
"name": "Les traitements ciblant les kinases Aurora sont-ils combinés avec d'autres thérapies ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont souvent combinés avec la chimiothérapie ou la radiothérapie pour améliorer l'efficacité."
}
},
{
"@type": "Question",
"name": "Y a-t-il des essais cliniques sur les kinases Aurora ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, plusieurs essais cliniques évaluent l'efficacité des inhibiteurs de kinases Aurora dans divers cancers."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des anomalies des kinases Aurora ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la progression rapide du cancer et la résistance aux traitements."
}
},
{
"@type": "Question",
"name": "Les anomalies des kinases Aurora augmentent-elles le risque de métastases ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surexpression des kinases Aurora est souvent associée à une augmentation des métastases."
}
},
{
"@type": "Question",
"name": "Comment les anomalies des kinases Aurora affectent-elles le pronostic ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont souvent liées à un pronostic défavorable en raison de la croissance tumorale agressive."
}
},
{
"@type": "Question",
"name": "Les complications des traitements ciblant les kinases Aurora sont-elles fréquentes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications comme des infections et des troubles sanguins peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les anomalies des kinases Aurora peuvent-elles affecter la réponse immunitaire ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent altérer la réponse immunitaire, rendant le corps moins efficace contre le cancer."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque associés aux anomalies des kinases Aurora ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux de cancer, l'exposition à des agents cancérigènes."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'anomalies des kinases Aurora ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque d'anomalies des kinases Aurora augmente généralement avec l'âge."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque pour les kinases Aurora ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu pour plusieurs types de cancer associés aux kinases."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans les anomalies des kinases Aurora ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en graisses et en sucres peut augmenter le risque de cancer et d'anomalies."
}
},
{
"@type": "Question",
"name": "Les infections virales sont-elles liées aux anomalies des kinases Aurora ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales, comme le HPV, sont associées à des cancers où les kinases Aurora sont impliquées."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 25/03/2025
Contenu vérifié selon les dernières recommandations médicales
5 publications dans cette catégorie
Affiliations :
Department of Genetics, Rutgers University, Piscataway, NJ 08854, USA.
Publications dans "Aurora kinases" :
3 publications dans cette catégorie
Affiliations :
Department of Genetics; Rutgers, The State University of New Jersey, Piscataway, New Jersey, United States of America.
Human Genetics Institute of New Jersey; Piscataway, New Jersey, United States of America.
Publications dans "Aurora kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Genetics, Rutgers University, Piscataway, NJ 08854, USA.
Department of Theriogenology, Faculty of Veterinary Medicine, Mansoura University, Mansoura 35516, Egypt.
Publications dans "Aurora kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Oncology, the First Affiliated Hospital of Gannan Medical College, Ganzhou, China.
Publications dans "Aurora kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Thoracic surgery, the First Affiliated Hospital of Dalian Medical University, Dalian, China.
Publications dans "Aurora kinases" :
2 publications dans cette catégorie
Affiliations :
Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
Publications dans "Aurora kinases" :
2 publications dans cette catégorie
Affiliations :
Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
Publications dans "Aurora kinases" :
2 publications dans cette catégorie
Affiliations :
Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China. liuq9@mail.sysu.edu.cn.
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China. liuq9@mail.sysu.edu.cn.
Publications dans "Aurora kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Physiology, Mie University Graduate School of Medicine, Tsu, Mie, 514-8507, Japan.
Publications dans "Aurora kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmaceutical Chemistry and Quality Assurance, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Mumbai 400056, India.
Publications dans "Aurora kinases" :
2 publications dans cette catégorie
Affiliations :
School of Pharmacy, Lanzhou University, Lanzhou 730000, China. Electronic address: chenshw@lzu.edu.cn.
Publications dans "Aurora kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Seton Hall University, South Orange, NJ, USA.
Department of Genetics, Rutgers University, Piscataway, NJ, USA.
Publications dans "Aurora kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Publications dans "Aurora kinases" :
2 publications dans cette catégorie
Affiliations :
Laboratoire de Spectrométrie de Masse Protéomique, Institute Curie, PSL Research University, Paris, France.
Publications dans "Aurora kinases" :
2 publications dans cette catégorie
Affiliations :
Laboratoire de Spectrométrie de Masse Protéomique, Institute Curie, PSL Research University, Paris, France.
Publications dans "Aurora kinases" :
2 publications dans cette catégorie
Affiliations :
Institut de Génétique et Développement de Rennes (IGDR), Unité CNRS, UMR 6290, Université de Rennes, 35043, Rennes, France.
Publications dans "Aurora kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Biophysics, All India Institute of Medical Sciences, Delhi 110029, India.
Publications dans "Aurora kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Biophysics, All India Institute of Medical Sciences, Delhi 110029, India.
Publications dans "Aurora kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Biophysics, All India Institute of Medical Sciences, Delhi 110029, India. Electronic address: punitkaur@aiims.edu.
Publications dans "Aurora kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, USA.
Publications dans "Aurora kinases" :
The gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) and its protein product have been widely studied for their role in cholesterol and lipid metabolism. PCSK9 increases the rate of...
Although the proprotein convertase subtilisin kexin-9 inhibitors (PCSK9i) were shown to significantly lower low-density lipoprotein and reduce atherosclerotic cardiovascular disease events in clinical...
Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its tissues and organs. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme rel...
To determine the harms of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in people who need lipid-lowering therapy....
This systematic review included randomised controlled trials that compared PCSK9 inhibitors with placebo, standard care or active lipid-lowering comparators in people who need lipid-lowering therapy w...
We included 32 trials with 65 861 participants (with the median follow-up duration of 40 weeks, ranging from 24 to 146 weeks). The meta-analysis showed an incidence of injection-site reaction leading ...
PCSK9 inhibitors slightly increase the risk of severe injection-site reaction but not cataracts, gastrointestinal haemorrhage, neurocognitive events, new-onset diabetes or severe myalgia or muscular p...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new target for reducing low-density lipoprotein cholesterol and incident cardiovascular disease, including stroke. However, the clinical rele...
In community-dwelling Japanese men (n = 526) aged 46-82 years without a history of cardiovascular disease, the associations of serum PCSK9 levels with the prevalence of CSVD and ICAS were assessed usi...
The median (interquartile range) age at baseline and serum PCSK9 levels were 69 (63-74) years and 240 (205-291) ng/ml, respectively. After adjusting for traditional cardiovascular risk factors includi...
Higher circulating PCSK9 levels were independently associated with an ICAS prevalence but not with CSVD prevalence. The quantification of circulating PCSK9 levels may help to identify individuals at h...
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a posttranslational regulator of the LDL receptor (LDLR). Recent studies have proposed a role for PCSK9 in regulating immune responses. Using R...
Guidelines advocate for intensive lipid-lowering in patients with atherosclerotic cardiovascular disease (ASCVD). In May 2020, evolocumab, a proprotein convertase subtilisin-kexin type 9 (PCSK9) inhib...
To identify barriers to prescribing PCSK9 inhibitors in hospitalised patients with ASCVD....
A retrospective 3-month, single-site, observational analysis was conducted in consecutive patients undergoing percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery. L...
Of 331 patients, 244 (73.7%) underwent PCI and 87 (26.3%) underwent CABG surgery. A lipid profile during or within 8 weeks of admission was measured for 202 (82.8%) patients undergoing PCI and 59 (67....
Prescribing of non-statin LDL-C-lowering therapies remains low in patients with ASCVD. Underprescribing of ezetimibe and suboptimal lipid testing rates are barriers to accessing subsidised PCSK9i ther...
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) levels have been suggested as novel atherosclerotic biomarker. PCSK9 plays important roles in the pathogenesis of atherosclerosis by regulating th...
This cross-sectional analysis enrolled 401 Caucasian patients with type II diabetes mellitus (T2DM). PCSK9 levels were measured by ELISA test, arterial stiffness was estimated by measuring carotid-fem...
Patients were divided in three tertiles according to increasing value of PCSK9. From the I to the III tertiles, there was a significant increase in high sensitivity C-reactive protein (hs-CRP), fibrin...
Our study demonstrates a close association between circulating PCSK9 levels and PWV in T2DM subjects without previous CV events even after adjusting for well-known CV risk factor and pharmacological m...
Proprotein convertase subtilisin/kexin-type 9 inhibitor (PCSK9i) treatment reduces cardiovascular events when taken over a long time for secondary prevention. Data on treatment adherence are scarce an...
Baseline data and prescription patterns of all 7302 patients with PCSK9i prescriptions dispensed on the account of Austrian Social Insurances between September 2015 and December 2020 were retrieved an...
Considering the high PDC and low discontinuation rates, the majority of patients adhere to PCSK9i treatment. Hence, in a system where PCSK9i treatment is made available at virtually no costs for patie...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces low density lipoprotein (LDL) uptake, leading to increased plasma levels of LDL. In addition, PCSK9 has been implicated in inflammation in...